Introduction
Dry eye disease (DED) is a multifactorial disorder of the tear film and ocular surface characterized by loss of tear film homeostasis, inflammation, epithelial compromise, and neurosensory abnormalities. Although many patients respond to conventional therapies such as lubricants, lid disease management, anti-inflammatory drops, and environmental modification, a subset develops persistent ocular surface damage or symptomatic flares that may warrant more intensive treatment. In these situations, amniotic membrane (AM) therapy can be a useful in-office option to support ocular surface healing.
For clinicians, the key questions are practical: which dry eye patients are most appropriate for AM therapy, when should it be considered, and how should it be implemented in office workflow? A structured approach can help integrate AM into dry eye management while maintaining realistic expectations and continuity of care.
Why Amniotic Membrane May Help in Dry Eye Disease
Amniotic membrane is used in ocular surface disease because it provides a biologically active substrate that can support epithelial healing and help modulate the ocular surface environment. In clinical practice, AM is generally considered when there is evidence of significant epithelial disease, inflammation, or surface breakdown that has not adequately improved with standard therapy alone.
In the setting of DED, potential goals of AM placement may include promoting re-epithelialization, reducing surface stress during acute exacerbations, and creating an environment more favorable to recovery of the corneal epithelium. It should be viewed as an adjunctive therapy rather than a replacement for identifying and treating the underlying drivers of disease, such as meibomian gland dysfunction, exposure, lagophthalmos, ocular rosacea, medication toxicity, autoimmune disease, or neurotrophic compromise.
Patient Selection: Who May Benefit
AM therapy is typically most relevant for patients with moderate to severe ocular surface involvement rather than uncomplicated mild evaporative symptoms. Candidates may include patients with:
Persistent punctate epithelial erosions despite lubrication and anti-inflammatory therapy
Recurrent epithelial breakdown or filamentary keratitis associated with DED
Significant ocular surface staining with symptoms out of proportion to routine treatment response
Acute inflammatory flares of severe dry eye, including cases associated with Sjögren syndrome or graft-versus-host disease
Exposure-related surface compromise when the epithelium is not adequately protected by standard measures
Ocular surface disease following surgery or medication toxicity when dry eye and epithelial instability are prominent contributors
Patient selection should be guided by both symptoms and signs. AM is usually better suited to patients with visible epithelial compromise than to those with symptoms alone and minimal staining. Clinicians should also evaluate whether pain may reflect a neuropathic component, since AM may improve the surface without fully addressing centrally mediated discomfort.
A careful history and examination remain essential. Document symptom chronicity, prior therapies, preservative exposure, systemic autoimmune disease, facial nerve dysfunction, incomplete blink, contact lens wear, and previous ocular surgery. Slit-lamp evaluation should assess staining pattern, tear meniscus, tear breakup time, conjunctival inflammation, lid margin disease, lagophthalmos, and corneal sensitivity when neurotrophic disease is a concern.
When to Consider Escalation to Amniotic Membrane
In-office AM treatment is generally considered after failure of appropriately targeted first-line and second-line measures, or earlier when the ocular surface is acutely threatened. Examples of situations where escalation may be appropriate include:
Persistent corneal staining despite preservative-free tears, ointment, and lid-directed therapy
Inadequate response to topical anti-inflammatory treatment
Recurrent dry eye flares causing functional vision decline
Painful epithelial disease where a therapeutic surface cover may accelerate recovery
Patients in whom a bandage soft lens is undesirable or insufficient, particularly when biologic support is desired
Timing matters. AM may be most useful when introduced before chronic epithelial compromise leads to a prolonged cycle of inflammation and poor healing. At the same time, it should not delay additional workup when infectious keratitis, limbal stem cell deficiency, severe neurotrophic keratopathy, or occult exposure problems are in the differential.
Practical In-Office Protocols
Protocols vary by product format and practice style, but several principles are broadly applicable.
Before placement, confirm the indication and rule out active infection or other diagnoses requiring alternative management. Explain to the patient that AM is intended to help the ocular surface heal and that temporary blur, foreign body sensation, and awareness of a retention ring or membrane may occur depending on the device used. Discuss activity restrictions, medication instructions, and follow-up timing.
Topical anesthetic is commonly instilled before insertion. A lid speculum is usually unnecessary for most office-based placements. If using a self-retained device, the membrane is positioned onto the ocular surface and centered so it remains stable beneath the lids. If using a sheet form that requires additional fixation, placement technique will depend on the material and the clinician’s preferred method. Maintaining sterile technique and careful handling is important to preserve the integrity of the graft.
After insertion, verify comfort, position, and lid closure. Many clinicians continue nonpreserved lubrication and adjust concurrent medications based on the clinical picture. Preservative toxicity should be minimized. Patients should be instructed not to rub the eye and to call if pain worsens, the device dislodges, or vision declines unexpectedly.
Follow-up commonly occurs within several days to about one week, depending on severity and the retention method. At follow-up, assess membrane status, epithelial healing, corneal staining, symptom change, and whether additional treatment is needed. Some patients improve after a single application, while others may require repeat treatment as part of broader ocular surface rehabilitation.
Post-Placement Management and Long-Term Care
AM therapy should be integrated into a longitudinal dry eye plan. Once the acute surface problem improves, clinicians should reinforce maintenance strategies directed at disease mechanism. These may include preservative-free tears, meibomian gland treatment, punctal occlusion in selected cases, topical immunomodulatory therapy, moisture protection, nighttime ointment, or management of exposure and systemic contributors.
It is also helpful to reset expectations: AM may improve the epithelial surface and reduce the intensity of a flare, but it does not by itself cure chronic DED. Ongoing control of inflammation, tear film instability, and lid disease remains necessary to reduce recurrence.
Pearls and Pitfalls
AM tends to be most impactful when there is clear epithelial pathology to treat. It may be less satisfying in patients whose symptoms are driven primarily by dysesthesia without substantial staining. Attention to comorbid blepharitis, Demodex, conjunctivochalasis, or exposure can determine whether the benefit is durable. Finally, office teams should have a consistent process for patient counseling, insertion setup, coding support, and timely follow-up.
Used thoughtfully, AM therapy can be a valuable office-based tool for dry eye patients with significant ocular surface compromise, particularly when conventional therapy has not been enough to restore epithelial health.
Educational disclaimer: This article is for clinician education only and is not a substitute for independent medical judgment, product labeling, or individualized patient care decisions.